CNBG-Virogin Biotech

CNBG-Virogin Biotech is a strategic joint venture between China National Biotec Group (CNBG), a subsidiary of Sinopharm, and Virogin Biotech. The company specializes in the development of next-generation oncolytic virus therapies and mRNA-based immunotherapies for the treatment of various cancers. Its lead candidate, VG161, is an innovative oncolytic herpes simplex virus type 1 (HSV-1) that expresses multiple immune-stimulating factors, including IL-12, IL-15, and a PD-L1 blocker. By combining Virogin's proprietary Synerlytic™ platform with CNBG's robust clinical and manufacturing infrastructure, the entity aims to accelerate the global development of potent cancer treatments. The company is currently advancing several programs through clinical trials, focusing on solid tumors such as hepatocellular carcinoma and gastric cancer.